As both genomic and post-genomic analyses of pathogens and disease has advanced the production of successful recombinant vaccines we now require the strategies to both * select appropriate molecules and *deliver these vaccines effectively to stimulate protective immune responses.
Both candidate discovery and the tools for delivering vaccines effectively will be explored and discussed at this one day event.
Meeting Chair: Dr Eleanor Berrie, Clinical BioManufacturing Facility,
Development of recombinant vaccines against nematode species of ruminants
Professor Jacqui Matthews, Royal (Dick)
Development of a thermostable and transcutaneous adenovirus vector vaccine designed to induce broad CD8 T-cell responses to HIV
Professor J George Dickson, Director Institute of Biomedical & Life Sciences, South West London Academic
Development, evaluation and optimisation of HIV-1/ SIV genetic vaccine components to generate a large pool of CD8+T cell memory cells recognising multiple CTL epitopes is currently one of the primary strategies in HIV-1/SIV vaccination protocols. We have developed systems to desiccate and store at ambient temperatures adenovirus vaccine vectors. With the aim of stimulation very broad and strong CTL responses we have developed a cohort of adeno vaccine vectors for HIV in which full-size or fragmented gag genes including cross clade conserved-epitope recombinants fused to ubiquitin sequences. Vector test outcomes are being evaluated in DC and non DC cells, in mice and in NHP models.
Talk to be confirmed
Dr David Paton, Institute for Animal
Methods for delivery of GM vaccines to stimulate appropriate, protective responses
Dr David JM Lewis,
Can Mucosal Vaccines make Needles a Thing of the Past?
Dr. Valerie Ferro,
We have developed a delivery system composed of non-ionic surfactant vesicles and bile salts (bilosomes), which protect entrapped antigen against degradation in the gastrointestinal tract. This delivery system removes the need for live or attenuated vaccines and is ideal for oral delivery of synthetic peptides and recombinant proteins. An IgA response is induced locally, while systemically the immune response can be directed towards a Th1 or Th2 bias by altering the size of the vesicles, irrespective to the pathogenic origin of the antigen.
Recombinant avipoxvirus vaccines
Dr Michael A. Skinner,
Viruses of the avian poxvirus (avipoxvirus) genus represent a diverse and divergent group of poorly characterised viruses. Borrowing approaches developed for Vaccinia virus, Fowlpox virus (the type species) was developed as a live recombinant vaccine vector for use in poultry. Like the other well-known member of the genus, Canarypox virus, Fowlpox virus only causes disease in birds but it is nevertheless able to infect mammalian cells, express proteins and induce immune responses, both humoral and cellular, which may in some circumstances be protective. Blocked during morphogenesis (or before) in mammalian cells, they have extremely high safety profile as live recombinant vaccine vectors for use in humans and other mammals, as demonstrated in numerous clinical trials (recombinant Canarypox virus, used in prime-boost vaccination with recombinant protein, has recently returned the first indications of partial success in an HIV vaccine trial). Relatively low potency has been addressed by using prime-boost regimes and by co-expression of host cytokines or co-stimulators. New generation vectors may involve deletion of avipoxvirus immunomodulators to improve efficacy safely. The focus of our current work is to identify appropriate immunomodulators for deletion.
Clinical trials of a novel influenza vaccine
Sarah C. Gilbert, Reader in Vaccinology, Jenner Institute,
Currently licensed influenza vaccines are designed to induce antibodies against the polymorphic external proteins of the virus, chiefly haemagglutinin. They can achieve 80% effectiveness when the vaccine strain and circulating virus are well matched, but substantially less when the circulating virus changes, and are never as effective in those aged 65. Completely new versions are required to protect against possible pandemic viruses. The Jenner Institute is testing a new type of influenza vaccine using the conserved internal proteins of the virus to boost cellular immunity to all subtypes of influenza A with a single vaccine. Cellular immunity is an important component of natural immunity to influenza virus and the clinical trials are designed to examine the safety, immunogenicity and efficacy of this new type of influenza vaccine.
Optimizing vaginal responses to HIV vaccines
Professor Robin Shattock, St Georges University of London,
